Fundraising Fox

DermBiont

Boston, US · Founded 2016 · Delaware corporation · 13 employees on LinkedIn · 7 known investors

DermBiont develops SM-030, a topical drug candidate targeting melasma, a skin pigmentation disorder, by inhibiting PKC-beta to address the underlying cause of hyperpigmentation.

Biotech Digital Health Medical Devices

Founders & leadership

DermBiont was founded in 2016 by Robert Brucker.

RB

Robert Brucker

Robert BruckerFounder

KR

Karl R. Beutner

Karl R. BeutnerExecutive

NE

Nichola Eliovits

Nichola Eliovits inBoard MemberManaging Partner at Olive Tree Capital

MD

Max Dawson

Max DawsonExecutive

Board

WR

Wilder Ramsey

Wilder Ramsey inBoard directorPartner & Co-Founder at Toba Capital

JL

Jennifer LeeBoard director

DY

Daniel Yadegar

Daniel YadegarBoard directorCo-Founder and Chief Medical Officer at Newpath Partners

SB

Steven BastaBoard director

Investors · 7

Civilization Ventures Management, LlcTiburon · $1M – $10M

Joyance PartnersBerlin

Olive Tree CapitalBoston

Toba CapitalIrvine · $1M – $10M

Valia VenturesLondon · $50K – $50M

Newpath PartnersreportedBoston · $50K – $10Mvia Daniel Yadegar · board

Reported raises · per SEC filings

Form D private placements

$114.2M disclosed across 10 rounds · 2019–2023

▶$32.7MraisedNov 2024 · 72 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Daniel YadegarDirector
Steven BastaDirector
Karl R. BeutnerExecutive Officer, Director
Nichola EliovitsExecutive Officer, Director
Max DawsonExecutive Officer
Wilder RamseyDirector

Offering amount: $45.3M
Amount sold: $32.7M
First sale: Oct 2023
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$4.7MraisedMar 2023 · 69 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Karl R. BeutnerExecutive Officer, Director
Wilder RamseyDirector
Max DawsonExecutive Officer
Steven BastaDirector
Jennifer LeeDirector
Nichola EliovitsExecutive Officer, Director

Offering amount: $4.7M
Amount sold: $4.7M
First sale: Mar 2023
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$2.5MraisedSep 2022 · 11 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Steven BastaDirector
Wilder RamseyDirector
Karl R BeutnerExecutive Officer, Director
Jennifer LeeDirector
Max DawsonExecutive Officer
Nichola EliovitsExecutive Officer, Director

Amount sold: $2.5M
First sale: Sep 2022
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$830.3KraisedJan 2022 · 10 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Max DawsonExecutive Officer
Nichola EliovitsExecutive Officer, Director
Jennifer LeeDirector
Karl R. BeutnerExecutive Officer, Director
Ramsey WilderDirector
Steven BastaDirector

Offering amount: $830.3K
Amount sold: $830.3K
First sale: Dec 2021
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$28.8MraisedDec 2021 · 42 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Wilder RamseyDirector
Nichola EliovitsExecutive Officer
Steven BastaDirector
Max DawsonExecutive Officer
Jennifer LeeDirector
Karl R. BeutnerExecutive Officer, Director

Offering amount: $39.5M
Amount sold: $28.8M
First sale: Dec 2021
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$19.2MraisedAug 2021 · 9 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Steven BastaDirector
Jennifer LeeDirector
Wilder RamseyDirector
Karl R. BeutnerExecutive Officer, Director
Robert BruckerExecutive Officer
Nichola EliovitsExecutive Officer, Director

Offering amount: $19.2M
Amount sold: $19.2M
First sale: Aug 2021
Incorporated: Corporation, Delaware, 2016
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$6.6MraisedFeb 2021 · 19 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Wilder RamseyDirector
Steven BastaDirector
Nichola EliovitsExecutive Officer, Director
Robert BruckerExecutive Officer
Karl R. BeutnerExecutive Officer, Director

Offering amount: $15M
Amount sold: $6.6M
First sale: Feb 2021
Incorporated: Corporation, Delaware, 2016
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$7.2MraisedOct 2020 · 19 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Wilder RamseyDirector
Robert BruckerExecutive Officer
Nichola EliovitsExecutive Officer, Director
Steven BastaDirector
Karl R. BeutnerExecutive Officer, Director

Offering amount: $8M
Amount sold: $7.2M
First sale: Oct 2020
Incorporated: Corporation, Delaware, 2016
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Arcutis5 shared keywordsArcutis is a biopharmaceutical company focused on dermatology, developing treatments for immune-mediated skin diseases such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp psoriasis. It serves patients and healthcare professionals with therapies aimed at improving drug efficacy, safety, and tolerability.

Companies competing with DermBiont for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does DermBiont do?: DermBiont develops SM-030, a topical drug candidate targeting melasma, a skin pigmentation disorder, by inhibiting PKC-beta to address the underlying cause of hyperpigmentation.
Who founded DermBiont?: DermBiont was founded by Robert Brucker in 2016.
Who are DermBiont's investors?: DermBiont's investors include Civilization Ventures Management, Llc, Joyance Partners, Olive Tree Capital, Start Capital, Toba Capital, Valia Ventures, Newpath Partners.
How much funding has DermBiont raised?: DermBiont has disclosed $114.2M raised across 10 rounds.
Where is DermBiont headquartered?: DermBiont is headquartered in Boston, US.